Revised Interpretation of the Mutual Recognition Agreement (MRA) between Switzerland and Canada

31 January 2025 The Canada-Switzerland MRA on Medicinal Products: Drug GMP Compliance Certification, Sectoral Annex on GMP has been in force since 2000. The text of the MRA has not yet been revised as this interpretation was possible on the…

Read MoreRevised Interpretation of the Mutual Recognition Agreement (MRA) between Switzerland and Canada

Learning from case law: Outcome of appeal request concerning SPC applications in the case of Halozyme Inc. vs the UK Intellectual Property Office

This is an attempt to present the facts leading to the outcome of the appeal request concerning Supplementary Protection Certificates (SPCs) in the case of Halozyme Inc. vs the UK Intellectual Property Office (IPO). The parties concerned Halozyme Inc. vs…

Read MoreLearning from case law: Outcome of appeal request concerning SPC applications in the case of Halozyme Inc. vs the UK Intellectual Property Office

Validation rules for regulatory transactions in eCTD and non eCTD format, Health Canada

Validation rules for regulatory transactions in electronic Common Technical Document (eCTD) format Health Canada has updated the validation rules for regulatory transactions submitted in the eCTD format, to reflect recent and upcoming changes in its processes. These rules are built…

Read MoreValidation rules for regulatory transactions in eCTD and non eCTD format, Health Canada

Learning from Case Law: Mylan IRE Healthcare v European Commission (Case C-237/22) concerning orphan medicinal products

Last updated: 10 January 2025 To view updates, click on the ‘+’ sign below. This post is an attempt to to provide information on Case C-237/22 concerning Mylan IRE Healthcare v European Commission, including clarification of the concepts of “Significant…

Read MoreLearning from Case Law: Mylan IRE Healthcare v European Commission (Case C-237/22) concerning orphan medicinal products

Learning from Case Law: Opinion and judgement on Cases C-119/22 (MSD vs Teva) and C-149/22 (MSD vs Clonmel) on conditions under which SPCs may be granted for combination products in the EU

Last updated: 3 January 2025 To view updates, click on the ‘+’ below: This post is an attempt to to provide information on recent progress concerning two cases, one from the Finnish Market Court C-119/22 (Teva v MSD) and the…

Read MoreLearning from Case Law: Opinion and judgement on Cases C-119/22 (MSD vs Teva) and C-149/22 (MSD vs Clonmel) on conditions under which SPCs may be granted for combination products in the EU